Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $104.45 Average PT from Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have received a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $106.20.

A number of brokerages recently weighed in on GPCR. The Goldman Sachs Group raised shares of Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. Citizens Jmp lifted their price objective on Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a research report on Friday, December 12th. Stifel Nicolaus upped their target price on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Citigroup reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC boosted its position in shares of Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. HighTower Advisors LLC raised its stake in Structure Therapeutics by 3.6% during the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after buying an additional 320 shares during the period. State of Wyoming boosted its holdings in Structure Therapeutics by 29.7% in the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after acquiring an additional 403 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Structure Therapeutics by 9.4% in the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after acquiring an additional 413 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after acquiring an additional 444 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $71.41 on Friday. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The company has a 50 day simple moving average of $75.10 and a two-hundred day simple moving average of $44.15. The company has a market capitalization of $4.33 billion, a PE ratio of -58.53 and a beta of -2.06.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.